Great post, Guts. The market is just incapable of understanding the potential of compounding pharmacies. But the upcoming figures in the second quarter will help to brush the doubts away. In some cases being ahead of the market is the best place to be. As you say, Guts, $4 million per month from that revenue stream alone would make the current share price look incongruous or merely symbolic.